查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1692308

骨癌治療市場 - 全球產業規模、佔有率、趨勢、機會和預測（按骨癌類型、按治療類型、按地區和競爭細分，2020-2030 年預測）

Bone Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Bone Cancer Type, By Treatment Type, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球骨癌治療市場價值為 13 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 5.12%。全球骨癌治療市場是腫瘤學更廣泛領域內一個充滿活力且不斷發展的產業。它致力於解決骨癌帶來的獨特挑戰，骨癌可能是原發性的（起源於骨骼）或繼發性的（由身體其他部位的轉移引起）。該市場涵蓋了旨在診斷、管理和潛在治癒骨癌的各種治療和療法。例如，美國癌症協會估計，2022 年將有 3,910 例新的骨癌病例和 2,100 例死亡病例。原發性骨癌很少見，佔所有癌症的不到 1%。骨肉瘤是最常見的類型，其次是軟骨肉瘤和尤文氏肉瘤。

市場概況
預測期 2026-2030
2024 年市場規模 13億美元
2030 年市場規模 17.4 億美元
2025-2030 年複合年成長率 5.12％
成長最快的領域 標靶治療
最大的市場 北美洲

主要市場促進因素

技術進步

主要市場挑戰

有限的研究經費和資源

主要市場趨勢

標靶治療的進展

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球骨癌治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依骨癌類型（原發性骨癌、繼發性骨癌）
    • 依治療類型（化療、標靶治療、放射治療、手術、其他）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美骨癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第7章：歐洲骨癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太骨癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美骨癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲骨癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 埃及

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如果有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Amgen Inc
  • Baxter Inc
  • Bayer AG
  • ZetaMet technology
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Recordati Group
  • Takeda Pharmaceutical Company
  • Eli Lilly and Company
  • Spectrum Pharmaceuticals Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 17386

Global Bone Cancer Treatment Market was valued at USD 1.30 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.12% through 2030. The global bone cancer treatment market is a dynamic and evolving sector within the broader field of oncology. It is dedicated to addressing the unique challenges posed by bone cancers, which can be primary (originating in the bone) or secondary (resulting from metastasis from other parts of the body). This market encompasses a wide range of treatments and therapies aimed at diagnosing, managing, and potentially curing bone cancer. For instance, the American Cancer Society estimated 3,910 new bone cancer cases and 2,100 deaths in 2022. Primary bone cancers are rare, comprising less than 1% of all cancers. Osteosarcoma is the most common type, followed by chondrosarcoma and Ewing sarcomas.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.30 Billion
Market Size 2030USD 1.74 Billion
CAGR 2025-20305.12%
Fastest Growing SegmentTargeted Therapy
Largest MarketNorth America

Key Market Drivers

Technological Advancements

Technological advancements have played a pivotal role in reshaping the landscape of bone cancer treatment. Modern imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, have revolutionized the diagnosis and staging of bone cancer. These technologies offer unparalleled precision in locating and characterizing tumors, enabling healthcare professionals to make informed decisions about treatment. One of the most significant breakthroughs in bone cancer treatment is the development of targeted therapies. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, targeted therapies focus on specific molecules or pathways within cancer cells. This precision minimizes collateral damage to healthy tissues and reduces the side effects associated with treatment. Technological advancements have also led to the refinement of surgical procedures for bone cancer treatment. Minimally invasive techniques, such as robotic-assisted surgery and laparoscopy, allow for smaller incisions, faster recovery times, and reduced postoperative pain. The emergence of 3D printing technology has transformed the creation of customized prosthetics for bone cancer survivors. These prosthetics are tailored to fit each patient's unique anatomy, providing a higher level of comfort and functionality. This innovation significantly improves the quality of life for individuals who have undergone limb-sparing surgeries.

Key Market Challenges

Limited Research Funding and Resources

One significant challenge faced by the bone cancer treatment market is the relative rarity of bone cancer compared to other types of cancer, such as breast or lung cancer. Because of its lower prevalence, bone cancer research often receives fewer resources and funding allocations. This limitation can impede the development of innovative treatments and therapies specifically tailored to bone cancer. Conducting clinical trials and research related to bone cancer can be financially demanding. The costs associated with patient recruitment, data collection, and the development of new drugs or treatment modalities are substantial. Inadequate funding and resources can hinder the progress of clinical trials and limit the exploration of potential breakthroughs.

Key Market Trends

Advancements in Targeted Therapies

One significant trend in the global bone cancer treatment market is the rapid development of targeted therapies. Rather than employing broad-spectrum treatments like chemotherapy, precision medicine is gaining prominence. This approach involves identifying specific genetic mutations or molecular markers unique to an individual's cancer cells. Targeted therapies are designed to precisely target these markers, disrupting the growth and spread of cancer cells while sparing healthy tissues. This trend is improving treatment outcomes and reducing the side effects associated with traditional therapies. Immunotherapy is another burgeoning trend in bone cancer treatment. This approach harnesses the body's immune system to recognize and attack cancer cells. Immunotherapeutic drugs, such as immune checkpoint inhibitors, are being investigated for their potential to enhance the immune response against bone cancer. The development of personalized immunotherapies tailored to each patient's unique immune profile is on the horizon, offering promising avenues for treatment.

Key Market Players

  • Amgen Inc
  • Baxter Inc
  • Bayer AG
  • ZetaMet Technology
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Recordati Group
  • Takeda Pharmaceutical Company
  • Eli Lilly and Company
  • Spectrum Pharmaceuticals Inc

Report Scope:

In this report, the Global Bone Cancer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bone Cancer Treatment Market, By Bone Cancer Type:

  • Primary Bone Cancer
  • Secondary Bone Cancer

Bone Cancer Treatment Market, By Treatment Type:

  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Surgery
  • Others

Bone Cancer Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bone Cancer Treatment Market.

Available Customizations:

Global Bone Cancer Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Bone Cancer Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Bone Cancer Type (Primary Bone Cancer, Secondary Bone Cancer)
    • 5.2.2. By Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Others)
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Bone Cancer Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Bone Cancer Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bone Cancer Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Bone Cancer Type
        • 6.3.1.2.2. By Treatment Type
    • 6.3.2. Mexico Bone Cancer Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Bone Cancer Type
        • 6.3.2.2.2. By Treatment Type
    • 6.3.3. Canada Bone Cancer Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Bone Cancer Type
        • 6.3.3.2.2. By Treatment Type

7. Europe Bone Cancer Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Bone Cancer Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Bone Cancer Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Bone Cancer Type
        • 7.3.1.2.2. By Treatment Type
    • 7.3.2. Germany Bone Cancer Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Bone Cancer Type
        • 7.3.2.2.2. By Treatment Type
    • 7.3.3. United Kingdom Bone Cancer Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Bone Cancer Type
        • 7.3.3.2.2. By Treatment Type
    • 7.3.4. Italy Bone Cancer Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Bone Cancer Type
        • 7.3.4.2.2. By Treatment Type
    • 7.3.5. Spain Bone Cancer Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Bone Cancer Type
        • 7.3.5.2.2. By Treatment Type

8. Asia-Pacific Bone Cancer Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Bone Cancer Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bone Cancer Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Bone Cancer Type
        • 8.3.1.2.2. By Treatment Type
    • 8.3.2. India Bone Cancer Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Bone Cancer Type
        • 8.3.2.2.2. By Treatment Type
    • 8.3.3. South Korea Bone Cancer Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Bone Cancer Type
        • 8.3.3.2.2. By Treatment Type
    • 8.3.4. Japan Bone Cancer Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Bone Cancer Type
        • 8.3.4.2.2. By Treatment Type
    • 8.3.5. Australia Bone Cancer Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Bone Cancer Type
        • 8.3.5.2.2. By Treatment Type

9. South America Bone Cancer Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Bone Cancer Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bone Cancer Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Bone Cancer Type
        • 9.3.1.2.2. By Treatment Type
    • 9.3.2. Argentina Bone Cancer Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Bone Cancer Type
        • 9.3.2.2.2. By Treatment Type
    • 9.3.3. Colombia Bone Cancer Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Bone Cancer Type
        • 9.3.3.2.2. By Treatment Type

10. Middle East and Africa Bone Cancer Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Bone Cancer Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bone Cancer Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Bone Cancer Type
        • 10.3.1.2.2. By Treatment Type
    • 10.3.2. Saudi Arabia Bone Cancer Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Bone Cancer Type
        • 10.3.2.2.2. By Treatment Type
    • 10.3.3. UAE Bone Cancer Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Bone Cancer Type
        • 10.3.3.2.2. By Treatment Type
    • 10.3.4. Egypt Bone Cancer Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Bone Cancer Type
        • 10.3.4.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenge

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Amgen Inc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysi
  • 14.2. Baxter Inc
  • 14.3. Bayer AG
  • 14.4. ZetaMet technology
  • 14.5. Johnson & Johnson
  • 14.6. Novartis AG
  • 14.7. Pfizer Inc.
  • 14.8. Recordati Group
  • 14.9. Takeda Pharmaceutical Company
  • 14.10. Eli Lilly and Company
  • 14.11. Spectrum Pharmaceuticals Inc.

15. Strategic Recommendations

16. About Us & Disclaimer